Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| 1 |
iShares US Real Estate ETF
IYR
|
+$1B |
| 2 |
Tesla
TSLA
|
+$697M |
| 3 |
Microsoft
MSFT
|
+$447M |
| 4 |
Accenture
ACN
|
+$439M |
| 5 |
iShares MSCI Emerging Markets ETF
EEM
|
+$421M |
Top Sells
| 1 |
CRH
CRH
|
+$2.27B |
| 2 |
Meta Platforms (Facebook)
META
|
+$2.01B |
| 3 |
Texas Instruments
TXN
|
+$1.97B |
| 4 |
Starbucks
SBUX
|
+$1.61B |
| 5 |
Consumer Discretionary Select Sector SPDR Fund
XLY
|
+$1.07B |
Sector Composition
| 1 | Technology | 32.41% |
| 2 | Financials | 11.84% |
| 3 | Consumer Discretionary | 10.72% |
| 4 | Healthcare | 9.02% |
| 5 | Communication Services | 8.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
OKYO
2551
OKYO Pharma
OKYO
$80.9M
| $980K | ﹤0.01% |
961,000
| – | – |
|
2552
Stoke Therapeutics
STOK
$1.29B
| $980K | ﹤0.01% |
79,740
+47,239
| +145% | +$581K |
|
2553
Savara
SVRA
$615M
| $979K | ﹤0.01% |
231,005
+163,044
| +240% | +$691K |
|
2554
SGHC Ltd
SGHC
$6.39B
| $978K | ﹤0.01% |
269,435
+157,693
| +141% | +$572K |
|
2555
Tactile Systems Technology
TCMD
$301M
| $977K | ﹤0.01% |
66,885
+24,188
| +57% | +$353K |
|
2556
ArriVent BioPharma
AVBP
$800M
| $976K | ﹤0.01% |
41,522
+38,132
| +1,125% | +$896K |
|
2557
Tredegar Corp
TG
$279M
| $975K | ﹤0.01% |
133,827
+26,757
| +25% | +$195K |
|
2558
GoodRx Holdings
GDRX
$1.46B
| $973K | ﹤0.01% |
140,113
+130,219
| +1,316% | +$904K |
|
2559
Tango Therapeutics
TNGX
$727M
| $972K | ﹤0.01% |
126,281
+55,470
| +78% | +$427K |
|
2560
Allogene Therapeutics
ALLO
$251M
| $959K | ﹤0.01% |
342,973
+172,745
| +101% | +$483K |
|
2561
Donegal Group Class A
DGICA
$711M
| $957K | ﹤0.01% |
64,952
+18,132
| +39% | +$267K |
|
2562
Altimmune
ALT
$321M
| $956K | ﹤0.01% |
155,741
+75,064
| +93% | +$461K |
|
|
ADAM
2563
Adamas Trust, Inc. Common Stock
ADAM
$644M
| $955K | ﹤0.01% |
150,946
+117,206
| +347% | +$742K |
|
2564
Equity Bancshares
EQBK
$800M
| $953K | ﹤0.01% |
23,308
+16,595
| +247% | +$679K |
|
2565
Vitesse Energy
VTS
$968M
| $950K | ﹤0.01% |
39,528
+30,243
| +326% | +$727K |
|
2566
Alphatec Holdings
ATEC
$2.26B
| $948K | ﹤0.01% |
170,546
+133,653
| +362% | +$743K |
|
2567
Paysafe
PSFE
$827M
| $946K | ﹤0.01% |
42,167
+30,881
| +274% | +$693K |
|
2568
Stagwell
STGW
$1.35B
| $944K | ﹤0.01% |
134,421
+101,201
| +305% | +$711K |
|
2569
Sutro Biopharma
STRO
$74.3M
| $944K | ﹤0.01% |
273,019
+216,757
| +385% | +$749K |
|
2570
Olo Inc
OLO
$1.74B
| $943K | ﹤0.01% |
190,335
+152,214
| +399% | +$754K |
|
2571
E.W. Scripps
SSP
$257M
| $941K | ﹤0.01% |
418,588
+394,580
| +1,644% | +$887K |
|
2572
Erasca
ERAS
$443M
| $939K | ﹤0.01% |
343,930
+296,657
| +628% | +$810K |
|
2573
Mersana Therapeutics
MRSN
$35.6M
| $934K | ﹤0.01% |
19,781
+4,872
| +33% | +$230K |
|
2574
DoubleVerify
DV
$2.13B
| $933K | ﹤0.01% |
55,448
-53,447
| -49% | -$899K |
|
2575
Dillards
DDS
$8.97B
| $930K | ﹤0.01% |
2,424
+200
| +9% | +$76.7K |
|